PDCD1 and cancer: To prevent this process, in recent years, highly efficacious immune checkpoint inhibitors (anti-CTLA-4 and anti-PD-1, alone or in combination), whose role is to enhance immune response against cancer cells, were introduced into clinical practice and they revolutionized cancer immunotherapy [8].